Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Webcasts|August 12, 2020

The Ever-Changing World of Extractables and Leachables

Join global industry and regulatory experts as they discuss current E&L hot topics on pharmaceuticals, biopharmaceuticals and medical devices. Live: Wednesday, Sept. 9, 2020 at 9am EDT | 2pm BST | 3pm CEST On demand available after final airing until Sept. 9, 2021


Register free: http://www.biopharminternational.com/bp_w/leachables

Event Overview:

Join global industry and regulatory experts as they discuss E&L hot topics on pharmaceuticals, biopharmaceuticals and medical devices. Extractables and leachables are important considerations in the production of medical devices and medicinal products. While COVID-19 is around, new ventilators and delivery devices for vaccines require urgent testing. This conference offers insight into this ever-changing world of E&L.

Key Learning Objectives:

  • Gain insight to some of the most important areas of E&L relevant to medical devices and pharmaceuticals, for both small and large molecules
  • Discover the importance of a team in solving E&L challenges: those with regulatory knowledge, toxicologists and analytical chemists
  • Understand the science behind testing

Speakers: Andrew Feilden, European E&L Strategic Director, Hall Analytical

Ron Brown, Toxicologist, Risk Science Consortium

Charles Johnson, Chemist, Bibra

Philip Clay, Director and Principal Toxicologist, Chorley Consulting

Mike Hodgson, Analytical Scientist, Baxter

Andy Teasdale, Analytical Chemist, AstraZeneca

Time and Date: Wednesday, Sept. 9, 2020 at 9am EDT | 2pm BST | 3pm CEST

On demand available after final airing until Sept. 9, 2021.

Sponsors: Hall Analytical

VR Analytical

Register free: http://www.biopharminternational.com/bp_w/leachables


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.